title: [A clinical study of the efficacy and safety of secretory human interferon alpha-2a treatment for chronic hepatitis B].
abstract: OBJECTIVE
  To investigate the efficacy and safety of secreted interferon in treatment of chronic hepatitis B.
  
  
  METHODS
  A multi-center randomized open-label controlled clinical trial was carried out. The patients of the study group were treated by secretory human interferon alpha-2a, and the patients of the control group were treated with an ordinary interferon.
  
  
  RESULTS
  ALT normalization rate in the secreted interferon group was 48.3% and it was higher at the end of treatment than that of the control group, but there was no difference between the two groups at the end of the follow-up. HBV DNA dropped more in the study drug group, but there was no difference in the normalization rate between the two groups. HBeAg seroconversions in secreted interferon group and in the control interferon group were 19.0% and 18.4% respectively. The safety of the two types of interferon was satisfactory.
  
  
  CONCLUSIONS
  Secreted interferon was superior to ordinary interferon in ALT normalization and HBV DNA drop at the end of treatment in chronic hepatitis B patients, but there was no difference at the end of the follow-up. There was also no difference in HBeAg negative and HBeAg seroconversion between the two groups.
authors.affiliation: People's Hospital, Peking University, Beijing 100044, China.
authors.forename: Hao
authors.initials: H
authors.lastname: Wang
authors.forename: Qin-huan
authors.initials: QH
authors.lastname: Wang
authors.forename: Hui-fen
authors.initials: HF
authors.lastname: Wang
authors.forename: Ji-dong
authors.initials: JD
authors.lastname: Jia
authors.forename: Wen
authors.initials: W
authors.lastname: Xie
authors.forename: Xiao-qi
authors.initials: XQ
authors.lastname: Qin
mesh_terms: D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004279:DNA, Viral / Q000097:blood; D005500:Follow-Up Studies; D006515:Hepatitis B virus / Q000302:isolation & purification; D019694:Hepatitis B, Chronic / Q000628:therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins